🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2026

Confident Specific

Management expressed strong satisfaction with Q2 results, citing net sales up 9.3%, comps up 6.7%, and market share gains. They used language like 'significantly better than planned' and 'strong performance' but also noted caution for the second half due to macro uncertainty and consumer spending pressures.

Q3 2026

Confident Specific

Management consistently used phrases like 'exceeded our expectations', 'strong performance', 'momentum is on our side', and detailed specific drivers (e.g., comp of 6.3%, double-digit e-commerce growth). Language shows clear conviction in strategy execution.

Q4 2026

Confident Specific

Management repeatedly highlighted 'stronger than expected' results, 'record-breaking holiday performance', and 'market share gains in mass and prestige beauty'. They provided precise figures: comp sales +5.8%, net sales +11.8%, EPS $8.01 for the quarter. The tone was forward-looking but grounded in specific strategic initiatives and financial goals.

Q1 2027 latest

Confident Specific

Management uses precise figures (11.1% net sales growth, 5.3% comp, 15.5% EPS growth) and phrases like 'fundamentally strong', 'confident we will deliver', and 'strong first quarter performance' to convey certainty and control.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is stronger after this call. The company delivered a strong Q1 with 11.1% sales growth and 15.5% EPS growth, and raised its operating profit and EPS guidance. Management demonstrated confidence by increasing share buyback and maintaining margin discipline. However, they kept comp growth unchanged despite Q1 outperformance, implying caution on macro headwinds and competition. The key watch items are whether they can sustain market share gains in a more promotional environment and whether gross margin improvement from shrink reductions is sustainable. The next quarter's comp and gross margin trajectory will be critical to validate their balanced approach.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

Good quarter Investor Presentation One-Pager? Q1 2027

Revenue

$3.16B

+11.1% YoY

Operating Income

$448.3M

+11.6% YoY

Operating Margin

14.2%

+0.1pp YoY

Net Income

$340M

+11.6% YoY

What Went Right

Comparable sales +5.3% driven by 3.7% ticket and 1.6% traffic
Gross margin +100bps to 40.1% on lower shrink and higher merch margin
Diluted EPS +15.5% to $7.74, boosted by $555M share buyback

What to Watch

Q2 toughest comp of year; guided low-single-digit comp growth implied
Elevated fuel costs pressuring transportation, partly offset by supply chain productivity
Macro uncertainty and value-conscious consumers may pressure traffic

Management Guidance

Fiscal 2026 net sales growth maintained at 6% to 7%
Operating income growth raised to 6.5% to 9% (from 6% to 9%)
Diluted EPS raised to $28.36 to $28.80 (from $28.05 to $28.55)

Investor Lens

The Q1 beat reinforces Ulta's ability to deliver double-digit EPS growth despite a cautious consumer. Raised operating profit guidance and accelerated buybacks demonstrate confidence. Two-year stacked comps in high-single-digits suggest the core business is healthy, but macro headwinds and tougher comps warrant a measured tone. Overall, the thesis is strengthened.

From investor presentation · AI-generated analysis · Not investment advice

🔒

Premium Feature

Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance

Upgrade to Premium

Already a member? Log in

📈 STRONG Strong start to FY2026 with 11.1% revenue growth

Revenue

Revenue of $3.16B grew 11.1% YoY, above initial expectations. Comparable sales rose 5.3%, with broad-based category growth led by fragrance (+high teens) and haircare (+high single-digits).

Profitability

Net income increased 11.6% to $340M, with diluted EPS of $7.74 (+15.5%). Operating income grew 11.6% to $448M, outpacing revenue growth.

Margins

Gross margin expanded 100bps to 40.1%, driven by lower inventory shrink and higher merchandise margin. SG&A deleveraged 90bps to 25.8% of sales due to Space NK and strategic investments, partly offset by advertising leverage.

Balance Sheet

Cash & short-term investments of $221M, short-term debt of $145M. Inventory per square foot +1.4%. Capital expenditures of $58M. $1.3B remaining in buyback program after deploying $555M in Q1.

Key Risks

Management flagged macroeconomic uncertainty and fuel cost pressures. Q2 is the toughest comp of the year, with the guide implying a step down in comp growth. The beauty category remains competitive.

Outlook

Fiscal 2026 net sales growth maintained at 6%–7%, comp sales growth of 2.5%–3.5%. Operating income growth raised to 6.5%–9%, implying flat to slight operating margin improvement. EPS now $28.36–$28.80.

Generated by AI · Q1 2027 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q1 2027 Q1 2027 2026-06-02

Q1 fiscal 2026 delivered 11.1% net sales growth, 5.3% comp sales growth, and 15.5% EPS growth, with broad-based category strength and robust e-commerce gains. Guidance for the year remains strong, with increased EPS and buyback targets, despite a competitive and value-focused market.

Q4 2026 Q4 2026 2026-03-12

Net sales grew nearly 10% to $12.4B with strong Q4 performance, market share gains, and robust growth in fragrance, haircare, and wellness. Fiscal 2026 guidance calls for 6–7% sales growth, 2.5–3.5% comp growth, and EPS of $28.05–$28.55.

Q3 2026 Q3 2026 2025-12-04

Q3 net sales grew 12.9% to $2.9B, with comps up 6.3% and strong gains across all categories. Gross margin improved, but SG&A rose due to investments and incentive comp. FY2025 guidance was raised, with continued focus on innovation, digital, and international expansion.

Q2 2026 Q2 2026 2025-08-28

Net sales grew 9.3% to $2.8B with comp sales up 6.7% and strong gains across all categories. Guidance was raised for full-year sales and EPS, while the company expanded internationally and launched new digital and wellness initiatives.

Q1 2026 Q1 2026 2025-05-29

Q1 net sales grew 4.5% to $2.8B, with EPS up 3.6% to $6.70 and strong market share gains. Guidance for FY25 is cautious, projecting flat to 1.5% comp sales growth and EPS of $22.65–$23.20, reflecting macro and trade uncertainties.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.